



Stereotactic Body Radiotherapy

Guest Editor:

Dr. Gianluca Ingresso

Radiation Oncology Section,
Department of Medicine and
Surgery, University of Perugia,
06129 Perugia, Italy

Deadline for manuscript
submissions:

closed (10 September 2021)

Message from the Guest Editor

Dear Colleagues,

Stereotactic radiotherapy (SRT) is a treatment option curing cancer that creates highly conformal dose distributions with steep dose gradients, using advanced planning and treatment equipment. Stereotactic radiotherapy allows for the safe delivery of high doses of radiation to the target lesion, while sparing the surrounding critical organs. More specifically, in clinical practice, it is a useful tool in patients affected by limited metastatic disease, defined as an “oligometastatic state”, which is considered as an intermediate state between localized and widespread cancer. In patients with a limited number of metastases from a variety of primary sites, it seems that SRT might improve overall survival and disease-progression-free survival, with a limited cost in terms of treatment-related morbidity. SRT is also under investigation for the treatment of primary tumors, instead of surgery or conventional radiotherapy, such as for curing lung cancer and prostate cancer. For these reasons, this Special Issue will explore the use of stereotactic radiotherapy in the therapy of solid tumors.

Dr. Gianluca Ingresso

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)